Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
PARP inhibitors
combination therapy
predictive biomarkers
triple-negative breast cancer
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
08
11
2021
revised:
27
11
2021
accepted:
29
11
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and is known to be associated with a poor prognosis and limited therapeutic options. Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics that have demonstrated efficacy as monotherapy in metastatic
Identifiants
pubmed: 34959671
pii: ph14121270
doi: 10.3390/ph14121270
pmc: PMC8709256
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : Chercheur-Boursier Clinicien
Références
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Cancer Treat Rev. 2018 Jul;68:62-68
pubmed: 29870916
Gynecol Oncol. 2017 Dec;147(3):509-513
pubmed: 29037805
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33261142
Oncoscience. 2019 Jan 31;6(1-2):287-288
pubmed: 30800714
Ann Oncol. 2018 May 1;29(5):1203-1210
pubmed: 29635390
JCO Precis Oncol. 2019 Dec;3:1-6
pubmed: 35100699
Biomark Res. 2015 May 01;3:9
pubmed: 26015868
Ann Oncol. 2021 Jan;32(1):49-57
pubmed: 33098995
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Ann Oncol. 2020 May;31(5):590-598
pubmed: 32245699
Ann Oncol. 2018 Dec 1;29(12):2341-2347
pubmed: 30335131
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720
pubmed: 28765325
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
NPJ Breast Cancer. 2017 Aug 25;3:31
pubmed: 28948212
Mol Cancer Ther. 2014 Feb;13(2):433-43
pubmed: 24356813
Ann Oncol. 2018 Jan 1;29(1):154-161
pubmed: 29045554
Ann Oncol. 2021 Dec;32(12):1582-1589
pubmed: 34500047
NPJ Breast Cancer. 2016 Nov 16;2:16036
pubmed: 28721389
Pharmaceuticals (Basel). 2021 Aug 04;14(8):
pubmed: 34451860
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Clin Cancer Res. 2017 Nov 1;23(21):6468-6477
pubmed: 29093017
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):23891-23893
pubmed: 31712441
JCO Precis Oncol. 2018;2:
pubmed: 31501807
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Front Oncol. 2021 Oct 28;11:718871
pubmed: 34778033
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Semin Cancer Biol. 2021 Dec;77:67-82
pubmed: 33607245
NPJ Genom Med. 2021 Feb 22;6(1):17
pubmed: 33619265
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
Breast Cancer Res Treat. 2012 Sep;135(2):505-17
pubmed: 22875744
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
Nat Commun. 2021 May 3;12(1):2487
pubmed: 33941784
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Nat Med. 2019 Oct;25(10):1526-1533
pubmed: 31570822
Breast Cancer Res. 2017 Aug 25;19(1):99
pubmed: 28851423
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
Clin Cancer Res. 2017 Mar 15;23(6):1397-1406
pubmed: 27663600
Annu Rev Med. 2015;66:455-70
pubmed: 25341009
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
J Clin Oncol. 2015 Jun 10;33(17):1895-901
pubmed: 25847929
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
JCO Precis Oncol. 2018;2018:
pubmed: 30234181
Clin Cancer Res. 2017 Aug 1;23(15):4066-4076
pubmed: 28356425
Cancer. 2018 Jun 15;124(12):2498-2506
pubmed: 29660759
ESMO Open. 2018 Jun 20;3(4):e000361
pubmed: 29942664
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
Mol Cancer Ther. 2017 Dec;16(12):2892-2901
pubmed: 28958991
Nat Cancer. 2021 Jan;2(1):66-82
pubmed: 33738458
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Mol Cancer Ther. 2020 Jan;19(1):123-134
pubmed: 31597711
Nature. 2021 Feb;590(7846):486-491
pubmed: 33505028
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530
pubmed: 29246904
Oncologist. 2023 Jun 15;:
pubmed: 37318349
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
J Geriatr Oncol. 2019 Mar;10(2):337-345
pubmed: 30333088
Nat Med. 2013 Nov;19(11):1381-8
pubmed: 24202391
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
Cell. 2018 May 3;173(4):879-893.e13
pubmed: 29681456
Nat Rev Clin Oncol. 2015 Jan;12(1):27-41
pubmed: 25286972
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
NPJ Syst Biol Appl. 2017 Mar 6;3:8
pubmed: 28649435
Eur J Cancer. 2021 Sep;154:35-45
pubmed: 34243076
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301
pubmed: 31549216
J Clin Oncol. 2015 Jun 10;33(17):1902-9
pubmed: 25847936
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Cancer Cell. 2019 Jun 10;35(6):851-867.e7
pubmed: 31185210
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
Ann Oncol. 2020 Nov;31(11):1518-1525
pubmed: 32798689
BMC Cancer. 2020 Jun 3;20(1):507
pubmed: 32493233
Cancers (Basel). 2020 May 27;12(6):
pubmed: 32471249
Clin Cancer Res. 2021 Sep 1;27(17):4710-4716
pubmed: 34131002
Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326
pubmed: 33403015
Ann Oncol. 2021 Aug;32(8):983-993
pubmed: 34272041
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
J Natl Cancer Inst. 2014 May 19;106(6):dju089
pubmed: 24842883
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
JCO Precis Oncol. 2020 Nov;4:1034-1037
pubmed: 35050769
Cancer Discov. 2017 Sep;7(9):1006-1017
pubmed: 28450425
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Lancet Oncol. 2020 Dec;21(12):1611-1619
pubmed: 33271091
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
JAMA Oncol. 2019 Aug 01;5(8):1132-1140
pubmed: 31194225
Lancet Oncol. 2020 Oct;21(10):1269-1282
pubmed: 32861273
Clin Cancer Res. 2010 Dec 15;16(24):6159-68
pubmed: 20802015
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Nat Commun. 2020 May 29;11(1):2662
pubmed: 32471999
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Clin Cancer Res. 2014 Sep 15;20(18):4816-26
pubmed: 24963051
Ann Oncol. 2021 Dec;32(12):1590-1596
pubmed: 34520831
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Nat Commun. 2017 Oct 11;8(1):857
pubmed: 29021619
Ann Oncol. 2020 Dec;31(12):1606-1622
pubmed: 33004253
Clin Cancer Res. 2021 Sep 15;27(18):4983-4993
pubmed: 34131001
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713
pubmed: 29788099
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Clin Cancer Res. 2017 Nov 1;23(21):6400-6410
pubmed: 28790114
BMC Cancer. 2018 Mar 7;18(1):265
pubmed: 29514593
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5
pubmed: 30540933
Cancer Treat Rev. 2018 Jun;67:34-44
pubmed: 29753961
Semin Radiat Oncol. 2015 Oct;25(4):237-50
pubmed: 26384272
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
Ann Oncol. 2016 Aug;27(8):1532-8
pubmed: 27194814
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166